IDH2 and central nervous system cancer: The unique metabolic pathways in IDH-mutated glioma not only explain the slow-growing nature of this disease but also suggest that developing targeted strategies for IDH-mutant-specific metabolic patterns could be a valuable approach for future glioma therapeutics.